Insulin debate spurs push for generic biologics

The heat is on the FDA to find a way to approve a generic insulin, the oldest existing biologic on the market. And some observers say that the push is likely to spur a broader effort for a generic regulatory pathway for all biologics. Insulin has been used in form or another since the 1920s, but there has never been a generic form approved. Some $3.3 billion dollars a year is spent on insulin.

- read the report from FierceHealthcare
- here's the article from The New York Times

ALSO: Eli Lilly has decided to stop construction of a new insulin manufacturing plant in Virginia. Another 250 U.S. plant workers are losing their job as Lilly expands a biotech manufacturing facility in Ireland. Release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.